The clinical application of monoclonal antibodies in chronic lymphocytic leukemia. - Wikidata - wikimedia - TriplyDB

The clinical application of monoclonal antibodies in chronic lymphocytic leukemia.

The clinical application of monoclonal antibodies in chronic lymphocytic leukemia.

http://www.wikidata.org/entity/Q34310845

about

Immunotherapy in Chronic Lymphocytic Leukaemia (CLL)New developments in the treatment of chronic lymphocytic leukemia: role of obinutuzumab Novel CD20 monoclonal antibodies for lymphoma therapy Therapeutic potential and challenges of targeting receptor tyrosine kinase ROR1 with monoclonal antibodies in B-cell malignancies Glycoengineering of therapeutic antibodies enhances monocyte/macrophage-mediated phagocytosis and cytotoxicity Current treatment options for primary immune thrombocytopenia.Autoimmune cytopenias in chronic lymphocytic leukemia.Obinutuzumab: a novel anti-CD20 monoclonal antibody for previously untreated chronic lymphocytic leukemia.TLR9 Ligand (CpG Oligodeoxynucleotide) Induces CLL B-Cells to Differentiate into CD20(+) Antibody-Secreting Cells.Dextran as a generally applicable multivalent scaffold for improving immunoglobulin-binding affinities of peptide and peptidomimetic ligands.Harnessing the fcμ receptor for potent and selective cytotoxic therapy of chronic lymphocytic leukemia.Choosing first-line therapy for chronic lymphocytic leukemia.Recognition of antigen-specific B-cell receptors from chronic lymphocytic leukemia patients by synthetic antigen surrogates.Neutralization of (NK-cell-derived) B-cell activating factor by Belimumab restores sensitivity of chronic lymphoid leukemia cells to direct and Rituximab-induced NK lysis.State-of-the-Art Management of Patients Suffering from Chronic Lymphocytic Leukemia.Cell death signaling and anticancer therapy Association between polymorphism of CD20 gene and chronic lymphocytic leukemia in Chinese population.Therapeutic advancement of chronic lymphocytic leukemia.Targeting Stereotyped B Cell Receptors from Chronic Lymphocytic Leukemia Patients with Synthetic Antigen Surrogates.Ibrutinib: an evidence-based review of its potential in the treatment of advanced chronic lymphocytic leukemia.Prognostic relevance of HER2/neu in acute lymphoblastic leukemia and induction of NK cell reactivity against primary ALL blasts by trastuzumab Targeted drug delivery and cross-linking induced apoptosis with anti-CD37 based dual-ligand immunoliposomes in B chronic lymphocytic leukemia cells.A phase I dose-finding trial of recombinant interleukin-21 and rituximab in relapsed and refractory low grade B-cell lymphoproliferative disorders Overview of recent developments in chronic lymphocytic leukemia.Lymphocyte cytosolic protein 1 is a chronic lymphocytic leukemia membrane-associated antigen critical to niche homing.Salvage therapy for relapsed chronic lymphocytic leukemia.Front-line therapy for chronic lymphocytic leukemia.Treatment of relapsed or refractory chronic lymphocytic leukemia.Targeting tetraspanins in cancer.Emerging monoclonal antibodies and related agents for the treatment of chronic lymphocytic leukemia.Lymphoproliferative disorders in immunocompromised individuals and therapeutic antibodies for treatment.Update on obinutuzumab in the treatment of B-cell malignancies.Ofatumumab for treating chronic lymphocytic leukemia: a safety profile.Stability of stock and diluted rituximab.New targeted therapies for malignant lymphoma based on molecular heterogeneity.Anti-CD20 monoclonal antibodies in chronic lymphocytic leukemia: from uncertainties to promises.Development of Novel Anti-Cd20 Monoclonal Antibodies and Modulation in Cd20 Levels on Cell Surface: Looking to Improve Immunotherapy Response PKD1 is critical for Epstein-Barr virus LMP1-induced protection of malignant B cells from cell death induced by rituximab.Comparative assessment of clinically utilized CD20-directed antibodies in chronic lymphocytic leukemia cells reveals divergent NK cell, monocyte, and macrophage properties.Generation and preclinical characterization of a Fc-optimized GITR-Ig fusion protein for induction of NK cell reactivity against leukemia.

P2860

Q26768154-AB6EADE3-3F7D-422C-B1AF-05A513843CFB Q26801292-AC889EB6-63A6-49C5-B248-1D276CA8B0B2 Q28390112-EF9DBCBF-F3A1-41D3-9597-47A26BFCB5D9 Q28478591-C7641F39-3B51-446F-851C-013C5228E9C5 Q28658712-CC4FA1C1-1D21-42FC-8F7C-551DE45B642D Q33394149-B8C83858-0E4A-4890-B3FF-D423B1A2E708 Q33407866-0738DE8C-5216-4136-8AB9-A807DEACC21B Q33416524-D452CDB8-DC5E-44DE-B63C-B0BD28308A23 Q33760295-E42581E7-986F-449A-9E3C-DB6BD5F20530 Q34431415-91826668-7DD9-4F40-8FA8-60F28AB9C413 Q34718363-9A932C9D-2FC8-40E5-A77B-9A09DCED6196 Q35124844-98D1449D-574F-4317-9993-7B527127D082 Q35482083-CF984532-34D4-459A-8DBA-E2E2FDC15719 Q35566828-1ED50A75-D32E-4E18-A191-627F4F133A54 Q35860550-064047EE-FA83-4604-906D-9FA00E6D32E4 Q35972102-9256936D-6355-4738-B10F-50C461E78B29 Q36046580-A6351A21-C10D-4398-8EE3-B9ECA801F5F9 Q36300303-D4E16DB0-048D-43BB-93B6-50110EDF025C Q36755058-697BE4A9-D6FB-4007-AF3D-0E519045077A Q36870866-5EE6875A-3F04-4C81-8C36-35C20DF5F73C Q37022365-FF301599-40F4-4037-9BAB-D796E8BBEF9D Q37129235-ED0E78DD-F6F6-4618-A302-FCCD2187A521 Q37265471-7EEAF42B-56A6-4BED-B7DD-80C1291F6106 Q37422201-2E64B4C1-6160-467D-888D-C30339150395 Q37635605-5E88F9B1-E8DD-4D39-87C2-D88726824451 Q37865547-534E7CB8-9F3B-43E9-B374-30AEFC9B905D Q37964914-DBB9437B-0416-46F2-BACC-31847BABB4CA Q37964916-D1E984EA-5751-4F88-891E-E2FC62DCAECD Q38033584-C0F6269B-95B5-4ECB-979E-560551013362 Q38068494-EF96B970-8CB2-465D-8558-D1533403824B Q38096060-D10AFE44-63F1-4CE7-ABBB-48C43316F638 Q38246230-BE1886EB-62D5-41F4-A833-9AB41AC89963 Q38632940-D1760C83-1F3F-40C1-9034-BEE8DDD5844F Q38759335-1681D937-C000-4180-BE14-19B628C24431 Q38787141-3BB5D4DD-6E40-4865-8745-D81E9AFE515E Q38824182-CAE63018-BC25-486F-8E04-5CA279834AAA Q38896113-5D51946C-0433-42DF-8FDD-7F49F27FC3C5 Q39007033-AA3AFB77-60EE-460B-A511-5F85F917C271 Q39192585-4528DB92-2FB5-487E-BE1B-D4DDD275429B Q39591125-FE71662C-E049-44D8-9CC4-32AB1484A466

P2860

The clinical application of monoclonal antibodies in chronic lymphocytic leukemia.

http://www.wikidata.org/entity/Q34310845

description

2010 nî lūn-bûn

@nan

2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

The clinical application of monoclonal antibodies in chronic lymphocytic leukemia.

@ast

The clinical application of monoclonal antibodies in chronic lymphocytic leukemia.

@en

The clinical application of monoclonal antibodies in chronic lymphocytic leukemia.

@nl

type

label

The clinical application of monoclonal antibodies in chronic lymphocytic leukemia.

@ast

The clinical application of monoclonal antibodies in chronic lymphocytic leukemia.

@en

The clinical application of monoclonal antibodies in chronic lymphocytic leukemia.

@nl

prefLabel

The clinical application of monoclonal antibodies in chronic lymphocytic leukemia.

@ast

The clinical application of monoclonal antibodies in chronic lymphocytic leukemia.

@en

The clinical application of monoclonal antibodies in chronic lymphocytic leukemia.

@nl

P1433

Q34310845-1DAE5211-CDD1-479F-97DC-79DBC85C1EF2

P1476

Q34310845-A2D023E4-7251-4B39-BFB9-4C6A163FEE2D

P2093

Q34310845-34AA3641-1CBE-4208-AD8D-F79E167ED41F

Q34310845-5C130C46-2A91-4064-9938-F040F4A74CE1

Q34310845-8CB14AA3-B1BA-43E6-87A8-DD851816EE6A

Q34310845-980BD504-423B-48A6-BD86-AE7303DE88BE

P2860

Q34310845-017159FB-9371-4349-BB18-9408838722DA

Q34310845-0973D8A6-1257-44F8-B55D-63ED5F9248ED

Q34310845-0BB716EC-A457-492B-907F-14B69737DC34

Q34310845-0BFECA83-9C4B-4D44-AC4A-AE2CDA53ED7E

Q34310845-0E8911A5-06E0-44CC-8C64-A6078EA6C001

Q34310845-17AAF734-BF98-4CBC-BDDE-F927CE013373

Q34310845-17CCE3A1-36EC-4F07-8A1F-FB090CE63193

Q34310845-19DE1769-95E8-41B1-BDBE-A830FE26B66C

Q34310845-20DF1D1B-0F80-4F86-B785-AEC8DCF568D8

Q34310845-257E2D2E-60FC-4BE6-9778-ACFF6C14D923

P304

Q34310845-304E3B9E-928E-4FF0-8BFF-EEA539A8959C

P31

Q34310845-24F9623D-5586-4CF7-8A57-A6BD79B531CC

P356

Q34310845-A50FCB9A-945A-477A-99AC-00460ACD747B

P407

Q34310845-0048256B-41D5-4762-B8F4-BCE5D60483C9

P433

Q34310845-BA23DC58-5329-4635-97B5-39493EE044DF

P478

Q34310845-EA6DB292-0E78-4517-967B-7E79C44846BB

P50

Q34310845-7B85D10E-14B9-46A0-901E-7EA0E28FB407

P577

Q34310845-1B81628E-D924-4D7E-BD8D-FCF7E13DD6B6

P5875

Q34310845-2A0A2511-7919-421B-9CF3-5E01FCF0D7EF

P698

Q34310845-CB87EFE1-2056-4748-8783-EF4BB92E3DF8

P921

Q34310845-369E025C-E797-47C0-A7B9-7919AF37CA6B

Q34310845-B7B12045-6435-484C-8075-E2766D79B120

Q34310845-D8E64BD1-8CC6-400C-BE02-A67F7F3AD9C3

P932

Q34310845-805204BD-39F6-4500-839A-C65C840C5EBD

P356

BLOOD-2010-04-001230

P1433

P1476

The clinical application of monoclonal antibodies in chronic lymphocytic leukemia.

@en

P2093

Lapo Alinari

http://www.w3.org/2001/XMLSchema#string

Natarajan Muthusamy

http://www.w3.org/2001/XMLSchema#string

Rosa Lapalombella

http://www.w3.org/2001/XMLSchema#string

Samantha M Jaglowski

http://www.w3.org/2001/XMLSchema#string

P2860

Fludarabine in the treatment of chronic lymphocytic leukemia: a review

Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia

Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical

Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions.

Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study

Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia

Fractionated subcutaneous rituximab is well-tolerated and preserves CD20 expression on tumor cells in patients with chronic lymphocytic leukemia.

The shaving reaction: rituximab/CD20 complexes are removed from mantle cell lymphoma and chronic lymphocytic leukemia cells by THP-1 monocytes.

Thrice-weekly low-dose rituximab decreases CD20 loss via shaving and promotes enhanced targeting in chronic lymphocytic leukemia.

Rituximab-CD20 complexes are shaved from Z138 mantle cell lymphoma cells in intravenous and subcutaneous SCID mouse models.

P304

3705-3714

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2010-04-001230

http://www.w3.org/2001/XMLSchema#string

P407

P433

19

http://www.w3.org/2001/XMLSchema#string

P478

116

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-07-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

45101702

http://www.w3.org/2001/XMLSchema#string

P698

20610811

http://www.w3.org/2001/XMLSchema#string

P921

P932

2981531

http://www.w3.org/2001/XMLSchema#string